Top Moderna Government Contract Awards

Top Moderna Government Contract Awards

Moderna is a pharmaceutical and biotechnology company best known for mRNA vaccine technology in COVID-19 vaccines. The company’s Moderna vaccine doses are supplied to the U.S. government and other public and private customers worldwide. Take a look at the top Moderna government contract awards.

1. Moderna Won the Contract for Manufacturing 100 Million Doses of the COVID-19 Vaccine

Moderna Inc. | Manufacturing 100 Million Doses of the COVID-19 Vaccine

  • Contracting activity: Department of Health and Human Services
  • Contract type: Firm-fixed-price contract
  • Value: $1.53 billion
  • Contract date: August 11, 2020

Moderna secured a contract to manufacture 100 million doses of the COVID-19 mRNA vaccine. Work commenced in Cambridge, Massachusetts, and was completed on March 31, 2022. The total contract amount of $1.53 billion was obligated at the time of the award.

On February 11, 2021, the U.S. Army Contracting Command pushed for an additional 100 million doses of the COVID-19 vaccine by July 31, 2021. This follow-up contract is worth $1.65 million. Around the same year, on June 15, 2021, the company was contracted to manufacture another 200 million doses of the COVID-19 vaccine by March 31, 2022, worth $3.3 billion.

2. Moderna Secured a Contract Modification to Manufacture an Additional 100 Million Doses for COVID-19

Moderna Inc. | Manufacture an Additional 100 Million Doses for COVID-19

  • Contracting activity: Biomedical Advanced Research and Development Authority and National Institutes of Health
  • Contract type: Modification to the contract
  • Value: $1.97 billion
  • Contract date: December 18, 2020

Moderna won a six-month contract modification to manufacture 100 million doses of the company’s mRNA vaccines against COVID-19. Biomedical Advanced Research and Development Authority and the National Institutes of Health used the first option for acetate-related efforts, worth $1.97 billion, with expected completion on June 30, 2021.

Along with previously awarded contracts and modifications from other federal agencies, Moderna supplied 300 million doses of the COVID-19 vaccine. The vaccine is available at no cost; healthcare payers, such as private insurance, Medicare or Medicaid, and an HHS program for uninsured Americans cover private administration.

3. Moderna Followed the Previously Awarded Contract for Pediatric Primary Series Vaccines

Moderna Inc. | Followed the Previously Awarded Contract for Pediatric Primary Series Vaccines

  • Contracting activity: Department of Health and Human Services
  • Contract type: Modification to the contract
  • Value: $17.47 million
  • Contract date: August 16, 2022

Moderna followed the previously awarded contract for the pediatric use of primary series vaccines. The total value of the contract, worth $17.47 million, from the Coronavirus Response and Relief Supplemental Appropriations Act funds of fiscal 2021 was obligated at the time of the award. Work is estimated to end by June 30, 2023.

Moderna’s contract modification follows the Food and Drug Administration’s recent announcement to authorize the procurement of COVID-19 vaccines for children as young as six months. The decision was made after the Moderna vaccine showed a comparable immune response to six months to five-year-old children who received a two-dose primary series of 25 mcg to adults who received two higher doses of the vaccine.

Moderna Inc. | Storage, Purchase, and Distribution of 65 Million Doses of COVID-19 Vaccine

  • Contracting activity: Department of Defense and Department of Health and Human Services
  • Contract type: Firm-fixed-price contract
  • Value: $1.74 billion
  • Contract date: July 28, 2022

The Department of Defense, in coordination with the Department of Health and Human Services, contracted for the purchase, storage, and distribution of 65 million doses of the Moderna vaccine for the fall vaccination program. The vaccine targets Omicron COVID-19 variants as the Food and Drug Administration recommended.

On August 1, 2022, the contract was modified to include the purchase of COVID-19 pediatric booster vaccines worth $52.60 million. Both contract awards are estimated for completion by March 27, 2024, with funding from Response and Relief Supplemental Appropriations Act funds of fiscal 2022.

5. Moderna Awarded a Contract to Develop a Vaccine Against the Novel Coronavirus SARS-CoV-2

Moderna Inc. | Develop a Vaccine Against Novel Coronavirus SARS-CoV-2

  • Contracting activity: Biomedical Advanced Research and Development Authority
  • Value: $483 million
  • Contract date: April 17, 2020

Moderna was one of the companies awarded to develop a vaccine against the novel coronavirus SARS-CoV-2. The award, worth $483 million, was used by the company to advance biotechnology research on mRNA technology, which was a candidate for the Food and Drug Administration’s licensure process.

On July 27, 2020, Moderna won another contract worth $472 million, increasing the total contract amount to $955 million. As part of Operation Warp Seed, the company planned to deliver 500 million to one billion potential COVID-19 vaccines in 2021, with Phase 3 tests completed by the end of 2020.

Frequently Asked Questions

What is Moderna Inc.?

Moderna Inc. is a pharmaceutical company based in Cambridge, Massachusetts. Founded in 2010, the company is headed by Stéphane Bancel, who has served as the Chief Executive Officer since October 2011. Moderna ranks 195th in the Fortune 500 companies of 2022, with a reported revenue of $3.4 billion in the third quarter of 2022.

Moderna focuses its development on messenger RNA (mRNA) technology on strengthening the body’s immune response. While the company is best known for developing the COVID-19 vaccine, it also delivers various drug modalities, such as prophylactic and therapeutic vaccinations, intratumoral immuno-oncology, and local treatments.

What is the Moderna vaccine for COVID-19?

Moderna vaccine for COVID-19, also known as mRNA-1273, uses mRNA vaccine technology, which teaches the body to create a protein to boost the immune system and prevent infection. The vaccine is safe and effective for children at six months old.

To develop the Moderna vaccine for COVID-19, the company has worked and entered into an agreement with several organizations and government agencies. Experts in mRNA technology, biotechnology, disease prevention, and law enforcement have developed, distributed, and inoculated the vaccine to eligible individuals.

Moderna collaborates with the following:

  • AstraZeneca
  • Merck & Co
  • Vertex Pharmaceuticals
  • National Institutes of Health
  • Biomedical Advanced Research and Development Authority
  • Defense Advanced Research Projects Agency
  • Bill & Melinda Gates Foundation
  • Karolinska Institute and Karolinska University Hospital
  • Institut Pasteur

Moderna: “Pioneering mRNA Technology”

Moderna government contract awards have improved access to COVID-19 vaccines worldwide. With its mRNA technology, the company continues to change the world of pharmaceuticals and medicine.

 

Video of the Day

GovCon Wire Logo

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings about Articles